This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR).
CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between
credit:
the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community.
The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.